---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-001724"
form_type: "8-K"
ticker: "LUCD"
cik: "0001799011"
company_name: "Lucid Diagnostics Inc."
filed_at: "2023-01-18T23:59:59+00:00"
generated_at: "2026-06-20T14:08:37.205646+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lucid/PAVmed cut 20% workforce, delay studies, halt products to reduce cash burn 25%

## Summary
- Workforce reduction of ~20% and other cost cuts aimed at lowering quarterly cash burn by at least 25%.
- Delays completion of EsoGuard BE-2 study to H2 2023; pauses EsoCure Esophageal Ablation device development.
- Maintains ~40 sales staff and nurse practitioners; shifts focus to large institutional accounts and satellite LTC program.
- PAVmed indefinitely pauses CarpX, PortIO, NextFlo product development; suspends annual cash bonuses.
- Veris Health delays implantable physiologic monitor development to H2 2023; prioritizes Cancer Care Platform adoption.

## SEC filing metadata
- accession: 0001493152-23-001724
- form_type: 8-K
- ticker: LUCD
- cik: 0001799011
- company_name: Lucid Diagnostics Inc.
- filed_at: 2023-01-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799011/000149315223001724/0001493152-23-001724-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799011/000149315223001724/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-001724
- JSON: https://secwatch.observer/filing/0001493152-23-001724.json
- Plain text: https://secwatch.observer/filing/0001493152-23-001724.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.